Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Denifanstat

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Ascletis Completes Phase 3 Enrollment for ASC40 in Acne Treatment
    Ascletis Completes Phase 3 Enrollment for ASC40 in Acne Treatment

    12 Nov 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ascletis-completes-enrollment-of-phase-iii-trial-of-asc40-denifanstat-once-daily-oral-tablet-for-treatment-of-acne-302302294.html

    PR NEWSWIRE
    12 Nov 2024
    Share Share
    Sagimet Bio Announces Presentations At AASLD Liver Meeting 2024
    Sagimet Bio Announces Presentations At AASLD Liver Meeting 2024

    16 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/10/16/2963912/0/en/Sagimet-Biosciences-Announces-Upcoming-Presentations-at-AASLD-The-Liver-Meeting-2024.html

    GLOBENEWSWIRE
    16 Oct 2024
    Share Share
    Sagimet Receives FDA Breakthrough Designation for Denifanstat
    Sagimet Receives FDA Breakthrough Designation for Denifanstat

    01 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//en/news-release/2024/10/01/2955945/0/en/Sagimet-Receives-FDA-Breakthrough-Therapy-Designation-for-Denifanstat-in-MASH.html

    GLOBENEWSWIRE
    01 Oct 2024
    Share Share
    Sagimet to Participate in Two Upcoming Investor Conferences
    Sagimet to Participate in Two Upcoming Investor Conferences

    04 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/04/2940469/0/en/Sagimet-Biosciences-to-Participate-in-Two-Upcoming-Investor-Conferences.html

    GLOBENEWSWIRE
    04 Sep 2024
    Share Share
    Sagimet Biosciences Reports Q2 2024 Financial Results And Corporate Updates
    Sagimet Biosciences Reports Q2 2024 Financial Results And Corporate Updates

    14 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/14/2930012/0/en/Sagimet-Biosciences-Reports-Second-Quarter-2024-Financial-Results-and-Provides-Corporate-Updates.html

    GLOBENEWSWIRE
    14 Aug 2024
    Share Share
    Sagimet Presents ITT And F3 Data From Phase 2b FASCINATE-2 At EASL 2024
    Sagimet Presents ITT And F3 Data From Phase 2b FASCINATE-2 At EASL 2024

    06 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/06/2894477/0/en/Sagimet-Biosciences-Presents-Data-from-ITT-and-F3-Patient-Population-in-Phase-2b-FASCINATE-2-Clinical-Trial-of-Denifanstat-at-EASL-International-Liver-Congress-2024.html

    GLOBENEWSWIRE
    06 Jun 2024
    Share Share